These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24210697)

  • 1. Decline in acute urinary toxicity: a long-term study in 2011 patients with prostate brachytherapy within a provincial institution.
    Chan EK; Keyes M; Pickles T; Lapointe V; Spadinger I; McKenzie M; Morris WJ
    Brachytherapy; 2014; 13(1):46-52. PubMed ID: 24210697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decline in acute urinary toxicities with increased institutional experience: 15-year experience of permanent seed prostate brachytherapy in a single Australasian institution.
    Ong WL; Matheson B; Millar J
    Brachytherapy; 2017; 16(2):313-322. PubMed ID: 28017293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
    Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?
    Keyes M; Schellenberg D; Moravan V; McKenzie M; Agranovich A; Pickles T; Wu J; Liu M; Bucci J; Morris WJ
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):825-34. PubMed ID: 16458775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
    Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation.
    Le Fur E; Malhaire JP; Nowak E; Rousseau B; Erauso A; Pene-Baverez D; Papin G; Delage F; Perrouin-Verbe MA; Fournier G; Pradier O; Valeri A
    Brachytherapy; 2013; 12(6):589-95. PubMed ID: 23669150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS).
    Tanaka N; Yorozu A; Kikuchi T; Higashide S; Kojima S; Ohashi T; Katayama N; Nakamura K; Saito S; Dokiya T; Fukushima M;
    Brachytherapy; 2019; 18(4):484-492. PubMed ID: 31072729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life.
    Sanmamed N; Chung P; Berlin A; Adleman J; Borg J; Lao B; Ghai S; Weersink R; Simeonov A; Rink A; Menard C; Helou J
    Brachytherapy; 2019; 18(4):477-483. PubMed ID: 31109872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy.
    Roeloffzen EM; Battermann JJ; van Deursen MJ; Monninkhof EM; Visscher MI; Moerland MA; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1072-9. PubMed ID: 20615621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy.
    Roeloffzen EM; van Vulpen M; Battermann JJ; van Roermund JG; Saibishkumar EP; Monninkhof EM
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):737-44. PubMed ID: 20888131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy.
    Crook J; Toi A; McLean M; Pond G
    Brachytherapy; 2002; 1(3):131-7. PubMed ID: 15090275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL.
    Dallas NL; Malone PR; Jones A; Doggart AJ; McConway KJ; Rogers PB
    BJU Int; 2012 Aug; 110(3):383-90. PubMed ID: 22332791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rectal toxicity and rectal dosimetry in low-dose-rate (125)I permanent prostate implants: a long-term study in 1006 patients.
    Keyes M; Spadinger I; Liu M; Pickles T; Pai H; Hayden A; Moravan V; Halperin R; McKenzie M; Kwan W; Agranovic A; Lapointe V; Morris WJ
    Brachytherapy; 2012; 11(3):199-208. PubMed ID: 21763213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute urinary retention after I-125 prostate brachytherapy in relation to dose in different regions of the prostate.
    Roeloffzen EM; Monninkhof EM; Battermann JJ; van Roermund JG; Moerland MA; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):76-84. PubMed ID: 20605364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.
    Thomas C; Keyes M; Liu M; Moravan V
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):447-55. PubMed ID: 18395357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peak flow rate is the best predictor of acute urinary retention following prostate brachytherapy: our experience and literature review.
    Ikeda T; Shinohara K
    Int J Urol; 2009 Jun; 16(6):558-60. PubMed ID: 19456987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning.
    Matzkin H; Kaver I; Stenger A; Agai R; Esna N; Chen J
    Urology; 2003 Sep; 62(3):497-502. PubMed ID: 12946754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation.
    Crook J; McLean M; Catton C; Yeung I; Tsihlias J; Pintilie M
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):453-60. PubMed ID: 11872292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute urinary retention after magnetic resonance image-guided prostate brachytherapy with and without neoadjuvant external beam radiotherapy.
    Landis DM; Schultz D; Cormack R; Tempany C; Beard C; Hurwitz M; O'Leary M; Albert M; Valentine K; D'Amico AV
    Urology; 2005 Apr; 65(4):750-4. PubMed ID: 15833521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.